All In Biotech

Drug Trial Radar · NCT03402152

NRX101 Glx Biomarker Validation Study

Validation of the Glx Biomarker for Treatment of Moderate Bipolar Depression With NRX-101

Last checked: Nov 19, 2026Latest source record: Aug 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8

Actual

Start

Nov 1, 2018

Primary completion

Jan 1, 2021

Study completion Jun 1, 2021

Sponsor

Lead sponsor
NeuroRx, Inc.Industry
Sponsor type
Industry
Collaborators
Target Health Inc.
First posted
Jan 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subnormal level of Glutamate+Glutamine (Glx) in the Anterior Cingulate Cortex (ACC) of the brain has been associated with depression and PTSD. Similarly, interventions that increase the level of Glx in the brain, specifically electroconvulsive therapy (ECT) and intravenous ketamine infusion have been associated with a rapid decrease in depression and suicidal ideation. This effect has been demonstrated in a dose-dependent manner in randomized clinical assessments. D-cycloserine, a glycine site modulator of NMDA receptor function has been demonstrated to increase Glx in the ACC of normal volunteers. The purpose of this study is to determine whether NRX-101, an experimental drug containing a fixed dose combination of D-cycloserine and lurasidone (1) raises Glx by a greater amount than either placebo or lurasidone alone in patients with bipolar depression, and (2) whether that elevation in Glx is correlated with a decrease in depression.

Conditions

  • Bipolar Depression
  • Suicidal Ideation

Interventions

  • NRX-101Drug

    NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth

  • Lurasidone HClDrug

    Lurasidone HCl will be given twice a day by mouth

  • PlaceboDrug

    Placebo oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GlxTime frame: Immediate

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New York State Psychiatric Institute

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.